Because azithromycin inhibits autophagy, which activates STUB1, it may be a potential therapeutic drug for pulmonary fibrosis by promoting degradation of both NOX4 and Smad3 (Table 1). This evidence concerns the gene NOX4 and pulmonary fibrosis.